智通财经APP讯，趣致集团(00917)发布公告，2025年7月15日(交易时段后)，本公司与配售代理订立配 售协议，配售代理有条件同意(作为本公司的配售代理)竭力促使承配人(其及其最终实益拥有人(倘适用) 将为独立第三方)购买300万股配售股份，配售价为每股配售股份106.60港元。 假设于本公告日期至交割日期期间已发行股份数目并无变动，配售事项下的 300万股配售股份相当于现 有已发行股份数目的约1.14%及经配发及发行配售股份扩大后已发行股份数目的约1.13%。 配售股份的配售价为每股106.60港元，较股份于2025年7月15日(即最后交易日)于联交所所报收市价每股 128.50港元折让约17.04%;及股份于截至2025 年7月14日(包括该日)，即紧接厘定配售价当日前最后交易 日止最后连续五个交易日于联交所所报平均收市价每股129.12港元折让约17.44%。 董事相信，配售事项将有利于增强本集团的流动性和财务状况，扩大本公司股东基础，优化本公司的资 本结构，并支持本公司的健康及可持续发展。 假设所有配售股份均获悉数配售且待交割后，预计配售事项最高所得款项总额及所得款项净额(经扣除 配售事项佣金及 ...

Core Viewpoint - Horizon Robotics is seeking to raise approximately $600 million through a placement of shares using a "old shares first" method, with a proposed share price range of HKD 6.87 to 7.08 [1] Group 1 - Horizon Robotics plans to issue shares to raise funds, indicating a strategic move to enhance its financial position [1] - The share price range for the placement is set between HKD 6.87 and 7.08, which reflects the company's valuation strategy [1]

Core Viewpoint - 康诺亚-B (02162.HK) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 864 million for various purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing about 7.72% of the company's issued shares as of the announcement date [2]. - The subscription involves 19 million new shares, accounting for approximately 6.36% of the enlarged share capital post-placement and subscription [2]. - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from about 27.79% to approximately 25.16% of the enlarged issued share capital [2]. Group 2: Pricing and Financial Details - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10 [2]. - The total expected proceeds from the subscription are approximately HKD 864 million, with net proceeds estimated at around HKD 854 million [2]. Group 3: Use of Proceeds - The net proceeds are planned to be allocated as follows: approximately 35% for R&D expenses related to CM512, CM518D1, and other pipelines; about 30% for the commercialization of the drug Siplizumab; around 25% for capital expenditures on manufacturing and R&D facilities; and 10% for general corporate and operational purposes [2].

Core Viewpoint - 康诺亚-B (02162) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 854 million for various development and operational purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing approximately 7.72% of the company's issued shares as of the announcement date [2]. - The number of subscription shares is 19 million, accounting for about 6.36% of the expanded share capital post-placement and subscription [2]. - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the subscription, estimated to be around HKD 854 million after deducting commissions and estimated expenses, will be allocated for: - Research and development expenses for CM512, CM518D1, and other pipeline projects [2]. - Commercialization of the drug Siplizumab [2]. - Capital expenditures for manufacturing and research facilities [2]. - General corporate and operational funding [2].

证券代码：002422 证券简称：科伦药业 公告编号：2025-046 四川科伦药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别风险提示： 特此公告。 本次配售的完成取决于配售协议约定的若干先决条件的达成，是否完成及最 终完成的时间存在不确定性，提请投资者注意投资风险。 四川科伦药业股份有限公司董事会 四川科伦药业股份有限公司（以下简称"公司"）近日获悉公司控股子公司 四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）根据其股东大会 的发行股份的一般性授权，于2025年6月5日与2名配售代理订立配售协议，根据 协议约定，配售代理同意促使向不少于6名承配人配售5,918,000股科伦博泰H股 股份，配售价格为331.8港元/股（以下简称"本次配售"），本次配售的完成取 决于配售协议约定的若干先决条件的达成。 本次配售所得款项净额预计为19.43亿港元，将用于科伦博泰的（1）产品的 研发、临床试验、注册备案、制造及商业化；（2）提升内部研发技术能力、加 强外部合作及拓展产品管线组合；（3）补充营运资金及作一般企业用途。 本次配售如依据配 ...

Group 1 - The company, Rongchang Biopharma (09995.HK), has entered into a placement agreement with Morgan Stanley and Huatai International to issue 19 million new H-shares at a placement price of HKD 42.44, which represents a discount of approximately 9.51% compared to the closing price of HKD 46.90 on May 21 [1] - The placement shares will account for about 10.02% of the existing issued H-shares and approximately 3.49% of the total issued shares as of the announcement date [1] - Assuming no other changes in the issued share capital, the placement shares will represent about 9.11% of the enlarged issued H-shares and approximately 3.37% of the total issued shares after the placement [1] Group 2 - The total estimated proceeds from the placement are approximately HKD 806 million, with net proceeds expected to be around HKD 796 million after deducting commissions and estimated expenses [2] - The company plans to use the net proceeds for the expansion of its core product, RC18, into key indications such as myasthenia gravis, membranous nephropathy, and for general corporate purposes [2]

Group 1 - The company, Wei Long Mei Wei (09985), has entered into a placement agreement to sell 80 million shares at a price of HKD 14.72 per share, which represents a discount of approximately 7.88% compared to the last closing price of HKD 15.98 [1][2] - The placement is expected to attract at least six professional or institutional investors, with no single investor anticipated to become a major shareholder post-placement [1] - The total expected gross proceeds from the placement and subscription are approximately HKD 1.178 billion, with net proceeds estimated at around HKD 1.167 billion after deducting commissions and estimated expenses [2] Group 2 - The funds raised from the placement and subscription are intended to enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term sustainable development [2] - The placement and subscription are expected to enrich the company's shareholder base by attracting high-quality institutional investors and further improve the liquidity of the shares [2] - The board believes that the terms of the placement and subscription agreements are fair and reasonable, aligning with the best interests of the company and its shareholders [2]